Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Numerous stakeholders have repeatedly called for improved health IT interoperability as a first step to improved healthcare but the Government Accountability Office (GAO) just released a report identifying ongoing barriers.
The Department of Health and Human Services Secretary will award $685 million to 39 national and regional healthcare networks and supporting organizations to help equip clinicians with the tools and support needed to improve quality of care, increase patients’ access to information and reduce costs.
The latest Centers for Medicare & Medicaid Services (CMS) funding will go toward efforts to reduce preventable hospital-acquired conditions and readmissions.
The FDA has created the Patient Engagement Advisory Committee which will provide advice to the FDA commissioner on a range of complex issues relating to medical devices, the regulation of devices and their use by patients.
Most people will experience at least one diagnostic error in their lifetime, according to a new report from the Institute of Medicine of the National Academies of Sciences, Engineering, and Medicine.
The Office of the National Coordinator for Health IT (ONC) is seeking public comments on the draft 2016 Interoperability Standards Advisory.
Getting motivating and informative text messages led patients with coronary heart disease to make behavior changes like exercising more and smoking less with concrete results, according to a study published in JAMA, the journal of the American Medical Association.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
